Vertex Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
VRTX Vertex Pharmaceuticals Inc
UTHR United Therapeutics Corp
GE General Electric Co
NKE Nike Inc
NFLX Netflix Inc
UNP Union Pacific Corp
AMTD TD Ameritrade Holding Corp
INO Inovio Pharmaceuticals Inc
MMS Maximus Inc
MITK Mitek Systems Inc
Go

Health Care : Biotechnology | Large Cap GrowthCompany profile

Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications. The Company's marketed medicines are ORKAMBI and KALYDECO. ORKAMBI (lumacaftor in combination with ivacaftor) is approved as a treatment for patients having two copies (homozygous) of the Delta-F508 (F508del) mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene. KALYDECO (ivacaftor) is approved for the treatment of CF patients having the G551D mutation or other specified mutations in their CFTR gene. The Company's development programs in the field of CF include Tezacaftor (VX-661), VX-152, VX-440, VX-659, VX-445 and VX-371. VX-152, VX-440, VX-659 and VX-445 are CFTR corrector compounds.

Price
Delayed
$167.85
Day's Change
-2.21 (-1.30%)
Bid
--
Ask
--
B/A Size
--
Day's High
171.41
Day's Low
165.61
Volume
(Light)

Today's volume of 700,442 shares is on pace to be much lighter than VRTX's 10-day average volume of 1,251,835 shares.

700,442
  • Prev Close
    170.06
  • Today's Open
    169.64
  • Day's Range
    165.61-171.41
  • Avg Vol (10-day)
    1.3M
  • Last (time)
    2:43p ET 12/17/18
  • Last (size)
    100
  • 52-Wk Range
    144.07 - 194.92
    LowHigh
  • (06/06/18 - 10/01/18)
    16.51%
  • 32.4%
  • Market Cap
    42.9B
  • Shares Outstanding
    255.6M
  • 2.50
  • 68.10x
  • No dividend
  • Ex-dividend
    No dividend
  • 1.6
  • 95.42
  • (% of float 11/30/18)
    1.50

Latest News

December 17, 2018
9:05 am ET
BusinessWire
December 13, 2018
8:00 am ET
BusinessWire
November 29, 2018
3:02 am ET
BusinessWire
November 27, 2018
8:00 am ET
BusinessWire
November 16, 2018
7:57 am ET
BusinessWire
November 14, 2018
7:25 am ET
Globe Newswire
November 10, 2018
9:54 am ET
MarketWatch
November 08, 2018
5:34 am ET
MarketWatch
November 05, 2018
8:00 am ET
BusinessWire
November 01, 2018
4:00 am ET
BusinessWire
October 24, 2018
4:01 pm ET
BusinessWire
October 19, 2018
7:54 am ET
BusinessWire
October 18, 2018
11:45 am ET
BusinessWire
October 16, 2018
4:01 pm ET
BusinessWire
October 11, 2018
3:40 pm ET
MarketWatch
October 10, 2018
4:01 pm ET
Globe Newswire
October 05, 2018
6:57 am ET
MarketWatch
October 01, 2018
8:02 am ET
BusinessWire
September 04, 2018
12:36 pm ET
MarketWatch
August 07, 2018
7:54 am ET
MarketWatch
June 29, 2018
8:41 am ET
MarketWatch
June 28, 2018
7:49 am ET
MarketWatch
Go to all current & historical news

Earnings Calendar and Events Data provided by |Terms of Use| © 2018 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2018. All rights reserved.